A Randomized, Controlled Phase 3 Study Of Pacritinib Versus Physician’s Choice In Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/Ìl)(PACIFICA) Read more
Individual Patient Supply Of Oral Pacritinib In A Patient With Thrombocytopenia And Primary Myelofibrosis. Read more
A Phase 1, First-In-Human, Dose Escalation Study Of JNJ-67571244 (Bispecific Antibody Targeting CD33 And CD3) In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) Read more
V-FAST: A Phase 1b Master Trial To Investigate CPX-351 Combined With Various Targeted Agents In Subjects With Previously Untreated Acute Myeloid Leukemia Read more
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered In Combination With Reduced-Intensity Chemotherapy, In Patients With Actively Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Read more
A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome? Read more
Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen. Read more
A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions Read more
A Phase 1b Dose Escalation Study Of Lemzoparlimab (TJ011133) In Combination With Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Read more
